You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

January 14, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Pharmacies face nationwide Tamiflu shortage

Pharmacies and physicians' offices across the country are reporting a shortage of Tamiflu to prevent and treat the flu, soon after CDC declared the illness an epidemic. » More on rationing Tamiflu

FDA defers to docs in use of pain therapies for pregnant women

Without adequate studies, FDA said use of pain medicines during pregnancy should be carefully weighed by healthcare providers.
» Key questions remain

Continuing Education

MTM opportunities in caring for the patient with cardiovascular disease

This month's CE activity is the last unit of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. Running from February 2014 through January 2015, the series enables pharmacists to earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to empower pharmacists to engage patients with cardiovascular disease in the practices of self-management.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT01-JKF33.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

2014 drug costs soar, no end in sight

While hepatitis C drugs Solvani, Harvoni, and Viekira Pak have been in the news recently because of their high price tag, and Express Scripts' and CVS Health's exclusive agreements with the drugmakers, they are not the only culprits in soaring drug costs.
» Details

 

RELATED ARTICLES

FDA grants waiver for influenza test

Naloxone price increases may threaten public safety

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group